Ayal Aizer
Overview
Explore the profile of Ayal Aizer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
674
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fischer G, Lamba N, Vogelzang J, Aizer A, Ligon K
Clin Cancer Res
. 2025 Jan;
31(4):719-732.
PMID: 39786469
Purpose: Melanoma brain metastases (MBM) are a common and lethal complication of metastatic melanoma. Despite improvements in treatments, subsets of patients with MBM experience rapid clinical decline, and currently, few...
2.
Christ S, Thiel G, Heesen P, Roohani S, Mayinger M, Willmann J, et al.
Radiat Oncol
. 2024 Oct;
19(1):148.
PMID: 39465396
Background And Introduction: Increasing evidence suggests that a subgroup of patients with oligometastatic cancer might achieve a prolonged disease-free survival through local therapy for all active cancer lesions. Our aims...
3.
Gandhi M, Ricciuti B, Harada G, Repetto M, Gildenberg M, Singh A, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300295.
PMID: 37972337
Purpose: rearrangements and activating point mutations represent targetable genomic alterations in advanced solid tumors. However, the frequency and clinicopathologic characteristics of wild-type amplification in cancer and its potential role as...
4.
Rahman R, Trippa L, Lee E, Arrillaga-Romany I, Fell G, Touat M, et al.
J Clin Oncol
. 2023 Sep;
41(36):5524-5535.
PMID: 37722087
Purpose: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for...
5.
Lamberti G, Aizer A, Ricciuti B, Alessi J, Pecci F, Tseng S, et al.
JCO Precis Oncol
. 2023 Feb;
7:e2200621.
PMID: 36809054
No abstract available.
6.
Dean J, Tanguturi S, Cagney D, Shin K, Youssef G, Aizer A, et al.
Neuro Oncol
. 2022 Nov;
25(6):1100-1112.
PMID: 36402744
Background: Glioblastomas comprise heterogeneous cell populations with dynamic, bidirectional plasticity between treatment-resistant stem-like and treatment-sensitive differentiated states, with treatment influencing this process. However, current treatment protocols do not account for...
7.
Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B, et al.
CA Cancer J Clin
. 2022 Jun;
72(5):454-489.
PMID: 35708940
Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their...
8.
Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery
Bredfeldt J, Miao X, Kaza E, Schneider M, Requardt M, Feiweier T, et al.
Phys Med Biol
. 2022 Jan;
67(6).
PMID: 35100574
In MRI-based radiation therapy planning, mitigating patient-specific distortion with standard high bandwidth scans can result in unnecessary sacrifices of signal to noise ratio. This study investigates a technique for distortion...
9.
Gupta S, Dawood H, Giantini Larsen A, Fandino L, Knelson E, Smith T, et al.
Front Oncol
. 2021 May;
11:662943.
PMID: 34026641
Introduction: Brain metastases are the most common brain tumors in adults, whose management remains nuanced. Improved understanding of risk factors for surgical complications and mortality may guide treatment decisions. Methods:...
10.
Verry C, Dufort S, Villa J, Gavard M, Iriart C, Grand S, et al.
Radiother Oncol
. 2021 May;
160:159-165.
PMID: 33961915
Background And Purpose: Brain metastasis impacts greatly on patients' quality of life and survival. The phase I NANO-RAD trial assessed the safety and maximum tolerated dose of systemic administration of...